# TUC3PII-01_TU2670 Phase IIa Clinical Study

> **NCT05138562** · PHASE2 · COMPLETED · sponsor: **TiumBio Co., Ltd.** · enrollment: 86 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Placebo Comparator: Placebo
- **DRUG:** Active Comparator: TU2670 320mg
- **DRUG:** Active Comparator: TU2670 240mg
- **DRUG:** Active Comparator: TU2670 120mg

## Key facts

- **NCT ID:** NCT05138562
- **Lead sponsor:** TiumBio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-19
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-08-05
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138562, "TUC3PII-01_TU2670 Phase IIa Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05138562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*